Ardelyx, Inc. (NASDAQ:ARDX) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET
Company Participants
Justin Renz - CFO & Treasurer
Michael Raab - President, CEO & Director
Susan Rodriguez - Chief Commercial Officer
Robert Blanks - Chief Regulatory Affairs & Quality Assurance Officer
Conference Call Participants
Christopher Howerton - Jefferies
Matthew Kaplan - Ladenburg Thalmann & Co.
John Bohnsack - Cowen and Company
Operator
Good afternoon, and welcome to the Ardelyx's Second Quarter 2022 Conference Call. [Operator Instructions]. As a reminder, today's call is being recorded.
I would now like to turn the call over to Justin Renz, Chief Financial Officer of Ardelyx. You may begin.
Justin Renz
Thank you, and good afternoon, everyone, and welcome to our second quarter financial results call. During this call, we will refer to the press release issued earlier today, which is available in the Investors section of the company's website at ardelyx.com.
On the call with me today are Mike Raab, President and CEO; and Susan Rodriguez, Chief Commercial Officer, with prepared remarks. Dr. Laura Williams, Chief Medical Officer; Dr. David Rosenbaum, Chief Development Officer; and Rob Blanks, Chief Regulatory Affairs and Quality Assurance Officer will join us for the question-and-answer period.
During this call, we will be making forward-looking statements that are subject to risks and uncertainties. Our actual results may differ materially from those described. We encourage you to review our risk factors in our quarterly report on Form 10-Q filed today, which can also be found on our website at ardelyx.com. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so even if our view should change.
And with that, I will pass the call over to Mike.
Michael Raab
Thank you, Justin, and good afternoon, everyone. It is a great pleasure that I provide you an update on our progress since our last call. First, for IBSRELA, I'm pleased to report that we continue to make great progress in our launch, laying the foundation for growth and meaningful market penetration of this important product. During these first 3 months of launch, the commercial team has made significant inroads in building demand for IBSRELA. Physicians are enthusiastic to have a novel drug added to their IBS-C treatment armamentarium and are responding favorably to the IBSRELA first-in-class mechanism and clinical data.
Integration of IBSRELA into already-established processes across GI offices is driving favorable prior authorization approval rates, thus enabling patient access for IBSRELA. Awareness and intent to prescribe the IBSRELA is growing with well-coordinated scientific engagement and education, our high-impact sales force efforts and broad-reaching Omnichannel initiatives.